CT 32228

CT 32228 is an inhibitor of lysophosphatidic acid acyltransferase-β (LPAAT-β) . CT 32228 inhibits tumor cell growth. CT 32228 exhibits IC50 values of around 0.1-0.8 μM in various leukemia cell lines. CT 32228 induces caspase activation in DHL-4 and Ramos cells. CT 32228 induces apoptosis when combined with Rituximab (HY-P9913) . CT 32228 results in a 50% xenograft growth delay in vivo. CT 32228 can be studied in research on acute leukemia[1][2].

Product Specifications

CAS Number

[521064-34-6]

UNSPSC

12352005

Target

Apoptosis

Related Pathways

Apoptosis

Field of Research

Cancer

Smiles

ClC1=CC(C2=NC(NC3=CC=C(C=C3)Br)=NC(N)=N2)=C(C)C=C1

Molecular Formula

C16H13BrClN5

Molecular Weight

390.66

References & Citations

[1]Douvas MG, et al., Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia. Leuk Res. 2006 Aug;30 (8) :1027-36.|[2]Pagel JM, et al., Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin Cancer Res. 2005 Jul 1;11 (13) :4857-66.